Syndax Pharmaceuticals (SNDX) Current Assets (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Current Assets of $471.2 million for Q1 2026, down 14.14% year-over-year from $548.8 million in Q1 2025, and down 10.78% quarter-over-quarter from $528.1 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Current Assets (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $471.2 million for Q1 2026.
- In Q1 2026, Current Assets fell 14.14% year-over-year to $471.2 million; the TTM figure through Mar 2026 stood at $471.2 million (down 14.14% YoY), while the FY2025 annual figure was $528.1 million, down 12.43% from the prior year.
- Current Assets for Q1 2026 stood at $471.2 million, down from $528.1 million in the prior quarter.
- The five-year high for Current Assets was $603.1 million in Q4 2024, with the low at $357.6 million in Q3 2022.
- The 5-year median for Current Assets is $453.9 million (2024), against an average of $470.6 million.
- The sharpest annual moves came in 2022 and 2026: Current Assets soared 50.59% in 2022, then slipped 14.14% in 2026.
- Syndax Pharmaceuticals' Current Assets stood at $489.8 million in 2022, then advanced by 18.6% to $580.9 million in 2023, then gained by 3.82% to $603.1 million in 2024, then fell by 12.43% to $528.1 million in 2025, then fell by 10.78% to $471.2 million in 2026.
- Business Quant data shows SNDX's Current Assets at $471.2 million in Q1 2026, $528.1 million in Q4 2025, and $529.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 675.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 675.04 Mn |
| Mar 31, 2026 | 471.18 Mn |
| Dec 31, 2025 | 528.08 Mn |
| Sep 30, 2025 | 529.83 Mn |
| Jun 30, 2025 | 531.68 Mn |
| Mar 31, 2025 | 548.75 Mn |
| Dec 31, 2024 | 603.06 Mn |
| Sep 30, 2024 | 414.81 Mn |
| Jun 30, 2024 | 446.06 Mn |
| Mar 31, 2024 | 453.90 Mn |
| Dec 31, 2023 | 580.88 Mn |
| Sep 30, 2023 | 380.97 Mn |
| Jun 30, 2023 | 409.08 Mn |
| Mar 31, 2023 | 441.51 Mn |
| Dec 31, 2022 | 489.79 Mn |
| Sep 30, 2022 | 357.63 Mn |
| Jun 30, 2022 | 392.29 Mn |
| Mar 31, 2022 | 420.06 Mn |
| Dec 31, 2021 | 448.40 Mn |
| Sep 30, 2021 | 238.25 Mn |